Associated tags: Education, Patient, American Liver Foundation, Research, Liver disease, ALF, Dietary supplement, Liver, MD, Fatty liver disease, Liver cancer, Pharmaceutical industry, Disease, NAFLD, Caregiver
Locations: NEW JERSEY, TX, NEW YORK, MOUNT SINAI, MS, CAPITOL HILL, UNITED STATES
Education,
Wilfrid Sellars,
University,
ALF,
Learning,
Liver disease,
Hospital,
Montefiore Medical Center,
Poster,
Communication,
NYU Langone Health,
Research,
Boston Medical Center,
American Liver Foundation,
Growth,
Hepatology,
Patient,
Fatty liver disease,
Associate,
Liver cancer,
Liver transplantation,
Knowledge,
Nursing NEW YORK, May 9, 2024 /PRNewswire/ -- Winners from the American Liver Foundation's 2024 Liver Health Poster Competition were announced today. This competition showcases posters and a brief video created by early career healthcare professionals from across the country on six areas of liver educational focus: disparities in liver disease, fatty liver disease (newly renamed to steatotic liver disease), liver cancer, liver transplantation, pediatric liver disease, and rare liver disease. Competitors are tasked with translating complicated medical information into a poster that can be easily understood by patients or the public.
Key Points:
- NEW YORK, May 9, 2024 /PRNewswire/ -- Winners from the American Liver Foundation's 2024 Liver Health Poster Competition were announced today.
- This competition showcases posters and a brief video created by early career healthcare professionals from across the country on six areas of liver educational focus: disparities in liver disease, fatty liver disease (newly renamed to steatotic liver disease), liver cancer, liver transplantation, pediatric liver disease, and rare liver disease.
- Winners from the American Liver Foundation's 2024 Liver Health Poster Competition were announced today.
- The 2024 Liver Health Poster Competition category winners are:
Eduardo A. Canto, Creighton University School of Medicine, for his presentation on disparities in liver disease .
Congress,
Fatty liver disease,
ALF,
Language,
NAFLD,
Liver disease,
Risk,
Hispanic,
AHRQ,
Overweight,
Diabetes,
FAST,
Partnership,
Agency,
Research,
American Liver Foundation,
Disease,
Obesity,
Labour,
NASH,
Patient,
Liver failure,
Society,
Metabolic syndrome,
American Society of Transplantation,
Liver transplantation,
Prevalence,
Dietary supplement NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.
Key Points:
- NEW YORK, April 25, 2024 /PRNewswire/ -- A first-ever national study to assess the prevalence of nonalcoholic fatty liver disease (NAFLD)* will be conducted by the Agency for Healthcare Research and Quality (AHRQ)**, in collaboration with other federal agency stakeholders, to evaluate the prevalence, diagnoses, treatments and complications associated with NAFLD.
- New national study to assess prevalence of NAFLD to be conducted, ALF grateful to Congress and advocates.
- "We are so grateful to Senator Bill Cassidy (R-LA) for his leadership in championing this effort on Capitol Hill.
- In an online liver health quiz to assess risk factors, 93% of respondents received a positive result for being at risk for NAFLD.
Retrieved on:
Wednesday, April 24, 2024
FAIRFIELD, N.J., April 24, 2024 /PRNewswire/ -- Today, American Liver Foundation mourns the passing of a leader on Capitol Hill, the Honorable Donald Payne, Jr, (D-NJ). A champion for patients affected by diabetes, obesity, kidney and liver disease among others, he was devoted to addressing the needs of underserved communities.
Key Points:
- FAIRFIELD, N.J., April 24, 2024 /PRNewswire/ -- Today, American Liver Foundation mourns the passing of a leader on Capitol Hill, the Honorable Donald Payne, Jr, (D-NJ).
- A champion for patients affected by diabetes, obesity, kidney and liver disease among others, he was devoted to addressing the needs of underserved communities.
- American Liver Foundation mourns passing of Congressman Donald Payne, Jr. a champion for patients and the underserved.
- "We are so grateful to Congressman Payne for his efforts to support our legislative priorities on behalf of liver patients and are deeply saddened by the unexpected news of his passing."
Congenital hepatic fibrosis,
ALF,
Liver disease,
Primary sclerosing cholangitis,
Health,
Partnership,
American Liver Foundation,
History,
Disease,
Boston Marathon,
Boston Athletic Association,
Memory,
Kostecki,
Liver cancer,
Running NEW YORK, April 12, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Boston Marathon Official Charity Program for the 2024 Boston Marathon®, which takes place on Monday, April 15, 2024.
Key Points:
- 128th Annual Boston Marathon is Monday, April 15th
NEW YORK, April 12, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) is proud to once again be a member of the Boston Marathon Official Charity Program for the 2024 Boston Marathon®, which takes place on Monday, April 15, 2024.
- American Liver Foundation (ALF) runners participate in the 2024 Boston Marathon® to raise awareness of liver disease!
- Since 1988, the American Liver Foundation Marathon Team has made a dramatic impact on the American Liver Foundation's mission.
- The American Liver Foundation team is made up of novice to experienced runners, most of whom have a connection to liver disease.
NEW YORK, April 11, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) has begun hosting its annual Liver Life Walk for 2024 at 20 in-person locations across the country. Liver Life Walk raises funds and awareness for liver disease and helps create life-long connections and networks of support between patients, families and all those affected by liver disease.
Key Points:
- Liver Life Walk raises funds and awareness for liver disease and helps create life-long connections and networks of support between patients, families and all those affected by liver disease.
- American Liver Foundation has begun hosting the 2024 Liver Life Walk at 20 in-person locations across the country.
"
- Liver Life Walk has been a signature event of American Liver Foundation since 1999," said Lorraine Stiehl, Chief Executive Officer of ALF.
- "Funds raised through the Liver Life Walk empowers ALF to continue providing valuable resources to liver patients and their families, fund critical liver disease research, and advance public health education and improved patient treatment and coverage."
Local,
Education,
Wrigley Mansion,
ALF,
American Liver Foundation,
Research,
Iron Chef,
Iron Chef America,
Restaurant,
Heart,
Table,
Liver disease NEW YORK, April 3, 2024 /PRNewswire/ -- The American Liver Foundation (ALF) has teamed up with world-renowned culinary expert Chef Christopher Gross and Celebrity Chef Mark Tarbell from Iron Chef for FLAVORS, a national culinary event to be held in Phoenix, Arizona on May 22, 2024.
Key Points:
- ALF and world-renowned culinary expert Chef Christopher Gross team up for FLAVORS, a national culinary event on May 22.
- "ALF is delighted for the return of FLAVORS with our founder, Chef Christopher," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
- "The generosity of these chefs and those philanthropists attending help us continue to provide life-saving resources, support, research and education for the nearly 100 million of Americans affected by liver disease."
- Chef Christopher will be joined by seven other local chefs, including Mark Tarbell, winner of 2007 "Iron Chef America".
American Liver Foundation,
Journey,
Celebration,
Liver disease,
Environment,
Caregiver,
Patient,
Social media,
News,
Liver transplantation,
MD,
ALF,
North Shore University Hospital,
Liver,
Partner,
Fatigue,
Sadness,
Dentistry April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.
Key Points:
- April is Donate Life Month and American Liver Foundation (ALF) has new patient resources, programs and support available to all liver transplant patients and the caregivers supporting them.
- "An informed patient is critically important to making the best decisions about care and ensuring the most favorable outcomes," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation and caregiver to a transplant recipient.
- Liver patients, families and loved ones are invited to celebrate the gift of life and the importance of liver transplantation.
- Throughout Donate Life Month ALF encourages patients, caregivers and organ donors to be part of the national conversation!
HCC,
Liver failure,
American Liver Foundation,
Fatty liver disease,
Liver disease,
Disease,
Caregiver,
Risk,
Cirrhosis,
Inflammation,
Chairperson,
Patient,
Life,
Liver transplantation,
Hope,
Doctor of Philosophy,
MASH,
MD,
ALF,
Pharmacotherapy,
Fibrosis,
NASH,
Hepatology,
Hepatocellular carcinoma,
NAFLD,
FDA,
Liver,
Food,
Pharmaceutical industry FAIRFIELD, N.J., March 14, 2024 /PRNewswire/ -- Today, the Food and Drug Administration (FDA) granted accelerated approval of a first of its kind drug therapy, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH) in patients who have progressed to fibrosis. NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease* (NAFLD) and causes inflammation in the liver and liver damage.
Key Points:
- NASH, now called metabolic dysfunction-associated steatohepatitis or MASH, is a dangerously progressive form of nonalcoholic fatty liver disease * (NAFLD) and causes inflammation in the liver and liver damage.
- "American Liver Foundation applauds the FDA approval of the groundbreaking new drug therapy treatment, resmetirom, for patients with NASH who have progressed to fibrosis," said Lorraine Stiehl , Chief Executive Officer, American Liver Foundation.
- American Liver Foundation offers many free resources to patients and families affected by liver disease.
- *Note: The nomenclature for NAFLD and NASH recently changed to metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) respectively.
Retrieved on:
Thursday, January 25, 2024
Cirrhosis,
Research,
Fibrosis,
ALF,
COVID,
Genetics,
Liver cancer,
Fatty liver disease,
Disease,
Patient,
Liver,
Doctor of Philosophy,
Biomarker,
American Liver Foundation,
Lipid metabolism,
Liver disease,
Dietary supplement FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research. Three researchers will receive a Liver Scholar Award, and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.
Key Points:
- Research topics include fatty liver disease, rare and pediatric liver disease, liver cancer, cirrhosis and more
FAIRFIELD, N.J., Jan. 25, 2024 /PRNewswire/ -- Today, the American Liver Foundation (ALF) announced ten new liver research awards that will fund early career scientists working in basic and translational liver disease research.
- Three researchers will receive a Liver Scholar Award , and seven will receive a Postdoctoral Research Fellowship Award to help advance research in liver biology and disease.
- ALF announces $850,000 in awards to fund early career scientists in basic and translational liver disease research.
- The 2023 research awards, totaling $850,000 over a three-year period, include research topics such as lipid metabolism, biomarkers, genetics, microbiome immune response, and liver environment, and address important questions in the pathophysiology of fatty liver disease (now called steatotic liver disease), pediatric liver disease , rare liver disease , liver cancer , fibrosis / cirrhosis , and alcohol-associated liver disease .
Retrieved on:
Tuesday, November 7, 2023
FAIRFIELD, N.J., Nov. 7, 2023 /PRNewswire/ -- The American Liver Foundation (ALF) is pleased to announce the winner of its 2023 Distinguished Scientific Achievement Award, Jeffrey V. Lazarus, PhD, MIH, MA, Professor of Global Health, CUNY Graduate School of Public Health and Health Policy, New York, who was recognized for his significant impact on viral hepatitis, metabolic dysfunction associated steatotic liver disease (MASLD) and global health. Dr. Lazarus is also Research Professor, Barcelona Institute for Global Health (ISGlobal), University of Barcelona, Spain. ALF will present the prestigious DSAA award to Dr. Lazarus during an evening reception held in his honor on November 13th in Boston, MA.
Key Points:
- American Liver Foundation announces 2023 Distinguished Scientific Achievement Award winner, Dr. Jeffrey V. Lazarus
"Dr. Lazarus is renowned for his unwavering dedication and service to the advancement of liver health," said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation.
- "For me, receiving the Distinguished Scientific Achievement Award marks an important expansion of the field to elevate public health and policy," said Dr. Lazarus.
- The 2022 winner of the Distinguished Scientific Achievement Award was David E. Cohen, MD, PhD of Brigham and Women's Hospital, Boston, MA.
- American Liver Foundation also offers a research awards program in three categories, Liver Scholar Award , Postdoctoral Research Fellowship Award , and a Travel Award , to provide necessary funding to help advance research in liver biology and disease.
